Document is current
Any future updates will be listed below
-
Authors
Kositz, Christian
Vasileva, Hristina
Mohammed, Nuredin
Achan, Jane
Dabira, Edgard Diniba
D’Alessandro, Umberto
Bradley, John
Marks, Michael
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03576313 at ClinicalTrials.govDocuments that mention this clinical trial
Risk factors for non-participation in ivermectin and dihydroartemisinin-piperaquine mass drug administration for malaria control in the MASSIV trial
https://doi.org/10.1186/s12936-024-04878-2
-
Funding
Funding for this research was provided by:
Wellcome Trust (217357/Z/19/Z)
- License Information
-
More Information
Article History
Received: 12 November 2023
Accepted: 10 February 2024
First Online: 22 February 2024
Declarations
:
: Ethical clearance for the MASSIV study was provided by the ethics board of the London School of Hygiene and Tropical Medicine, and the Gambian government/MRCG Joint Ethics Committee (Ethics Ref. Nr. 15823).
: The authors declare that they have no competing interests.
